english.prescrire.org > Spotlight > 100 most recent > Dupilumab (Dupixent°) in prurigo nodularis

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Dupilumab (Dupixent°) in prurigo nodularis

 Marketing Authorisations   Dupilumab, an immunosuppressive monoclonal antibody directed against interleukin-4 and interleukin-13 receptors, has been authorised in the European Union for the treatment of prurigo nodularis, a condition that can greatly impair patients' quality of life.
Full article available for download by subscribers

©Prescrire 1 July 2024

Source: "Dupilumab (Dupixent°) in prurigo nodularis" Prescrire Int 2024; 33 (261): 183-184. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
See also:

"Dupilumab (Dupixent°)
in severe atopic eczema
from 6 months of age"
Prescrire Int 2024;
33 (260): 151.
Subscribers only

"Dupilumab (Dupixent°)
in severe asthma from
6 years of age"
Prescrire Int 2023;